6-iodoquinoline-2,4(1H,3H)-dione | 658709-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-iodoquinoline-2,4(1H,3H)-dione
• 英文别名: 6-iodo-1H-quinoline-2,4-dione
• CAS: 658709-62-7
• 化学式: C₉H₆INO₂
• 分子量: 287.057
• InChiKey: BOUMFGOWEBRZCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  6-iodoquinoline-2,4(1H,3H)-dione 在 盐酸 、 sodium hydroxide 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 22.0h， 生成 4-chloro-6-iodoquinolin-2(1H)-one
  参考文献：
  名称：

  Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors

  摘要：

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.

  DOI：

  10.1021/jm502009h
• 作为产物：
  描述：

  3-((4-iodophenyl)amino)-3-oxopropanoic acid 在 PPA 作用下， 反应 5.0h， 生成 6-iodoquinoline-2,4(1H,3H)-dione
  参考文献：
  名称：

  [EN] 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
  [FR] DERIVES D'HETEROARYLES FUSIONNES EN 6,6 UTILISES COMME INHIBITEURS DE METALLOPROTEASES MATRICIELLES

  摘要：

  本发明提供了公式（I）或其药学上可接受的盐所定义的化合物，其中R?l，Q，Yl，Y2，Y3Y，R2a，R2b，R5¿和n如规范中所定义。本发明还提供了包含公式（I）化合物的制药组合物，并且提供了将公式（I）化合物用作基质金属蛋白酶抑制剂的用途。

  公开号：

  WO2004014388A1

文献信息

• Oxo-azabicyclic compounds
  申请人：——

  公开号：US20030216402A1

  公开（公告）日：2003-11-20

  A compound selected from those of formula (I): 1 wherein: X 1 , X 2 , and X 3 , represent N or —CR 3 in which R 3 is as described in the description, G 1 represents a group selected from those of formulae (i/a) and (i/b): 2 in which R 4 , R 5 , and R 6 are as defined in the description, G 2 represents a group selected from carbon-carbon triple bond, —CH═C═CH—, C═O, C═S, S(O) n1 in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c): 3 in which Y 1 represents O, S, —NH or —Nalkyl, and Y 2 represents O, S, —NH or —Nalkyl, n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, Z 1 represents —CR 9 R 10 , wherein R 9 and R 10 are as defined in the description, A represents a ring system, R 1 represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d): 4 in which p, Z 2 , B, q and G 3 are as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.

  从公式（I）中选择的一种化合物：其中：X1、X2和X3代表N或—CR3，其中R3如描述中所述，G1代表从下列公式（i/a）和（i/b）中选择的一种基团：其中R4、R5和R6如描述中所定义，G2代表从碳-碳三键、—CH═C═CH—、C═O、C═S、S(O)n1中选择的一种基团，其中n1表示从0到2的整数，或者从下列公式（i/c）中的一个基团：其中Y1代表O、S、—NH或—N烷基，Y2代表O、S、—NH或—N烷基，n是从0到6的整数，m是从0到7的整数，Z1代表—CR9R10，其中R9和R10如描述中所定义，A代表一个环系统，R1代表从H、烷基、烯基、炔基、可选择地取代和公式（i/d）中的一种基团：其中p、Z2、B、q和G3如描述中所定义，以及其光学异构体、N-氧化物和与药用酸或碱形成的加合盐，以及含有它们的药物产品对于作为第13型基质金属蛋白酶的特异抑制剂是有用的。
• 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040043985A1

  公开（公告）日：2004-03-04

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 1 , Y 2 , Y 3 , R 2a , R 2b , R 5 , and n are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、Y1、Y2、Y3、R2a、R2b、R5和n如规范中所定义。本发明还提供了药学组合物，包括由规范中定义的公式I的化合物或其药学上可接受的盐以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予公式I的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者内给予公式I的化合物或其药学上可接受的盐，单独或在药学组合物中。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、除骨关节炎或类风湿性关节炎之外的关节炎、心力衰竭、炎性肠病、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者内给予公式I的化合物或其药学上可接受的盐，单独或在药学组合物中。本发明还提供了组合物，包括公式I的化合物或其药学上可接受的盐，以及规范中描述的另一种药学活性成分。
• Matrix metalloproteinase inhibitors and methods for identification of lead compounds
  申请人：——

  公开号：US20040171543A1

  公开（公告）日：2004-09-02

  The invention relates to compounds that are selective inhibitors of matrix metalloproteinases, to pharmaceutical compositions containing them and to their use in the prevention and/or treatment of MMP-associated diseases. The invention also relates to methods for identification of lead compounds that are selective inhibitors of matrix metalloproteinases. The compounds have the properties that they: (a) bind allosterically to a matrix metalloproteinase or small group of metallic metalloproteinases; (b) bind into at least the S1′ pocket, at least the S1″ pocket (as defined) or at least the S1′ pocket and the S1″ pocket of said matrix metalloproteinase; and (c) exhibit selectivity for a matrix metalloproteinase or group of matrix metalloproteinases other than MMP-13.

  本发明涉及选择性抑制基质金属蛋白酶的化合物，包括含有它们的药物组成物，以及它们在预防和/或治疗与MMP相关的疾病中的应用。本发明还涉及识别选择性抑制基质金属蛋白酶的先导化合物的方法。这些化合物具有以下特性：(a)与基质金属蛋白酶或少量金属金属蛋白酶发生异构作用；(b)至少结合于所述基质金属蛋白酶的S1'口袋、至少结合于S1"口袋（如定义所述）或至少结合于所述基质金属蛋白酶的S1'口袋和S1"口袋；以及(c)表现出选择性，对MMP-13以外的基质金属蛋白酶或基质金属蛋白酶组具有选择性。
• [EN] MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS<br/>[FR] INHIBITEURS DE METALLOPROTEINASE MATRICIELLE ET PROCEDES D'IDENTIFICATION DE COMPOSES CHEFS DE FILE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014381A2

  公开（公告）日：2004-02-19
• OXO-AZABICYCLIC COMPOUNDS
  申请人：Warner-Lambert Company LLC

  公开号：EP1492775A2

  公开（公告）日：2005-01-05